Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bruno Arroja

Showing results (31-40 of 38) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 38 results.
GE Portuguese Journal of Gastroenterology|January 12, 2026
Comparison of Two Oral Iron Formulations for Iron Deficiency and Iron Deficiency Anemia in Inflammatory Bowel Disease: A Prospective StudyAndreia Guimarães, Tiago Leal, Tânia Carvalho, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 18, 2023
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximabPaula Sousa, Marta Patita, Bruno Arroja, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 YearsFernando Magro, Diogo Magalhães, Marta Patita, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
EARLY INTERVENTION PREVENTS DISEASE PROGRESSION IN ULCERATIVE COLITIS - A MULTICENTER RETROSPECTIVE STUDYJoana Camões Neves, Tiago Leal, Samuel Fernandes, et al.
United European Gastroenterology Journal|June 15, 2023
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective studyFernando Magro, Maria Manuela Estevinho, Gaia Catalano, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 13, 2020
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After BiopsyFernando Magro, Catarina Alves, Joanne Lopes, et al.
Pageof 4

Showing results (31-40 of 38) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
GE Portuguese Journal of Gastroenterology|January 12, 2026
Comparison of Two Oral Iron Formulations for Iron Deficiency and Iron Deficiency Anemia in Inflammatory Bowel Disease: A Prospective StudyAndreia Guimarães, Tiago Leal, Tânia Carvalho, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|November 18, 2023
Thiopurines have no impact on outcomes of Crohn's disease patients beyond 12 months of maintenance treatment with infliximabPaula Sousa, Marta Patita, Bruno Arroja, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 13, 2021
Subclinical Persistent Inflammation as Risk Factor for Crohn's Disease Progression: Findings From a Prospective Real-World Study of 2 YearsFernando Magro, Diogo Magalhães, Marta Patita, et al.
Journal of Crohn'S & Colitis|January 20, 2024
The Influence of Subclinical Active Inflammation on IFX Pharmacokinetic Modeling and Disease Progression Assessment: Findings from a Prospective Real-World Study in Inflammatory Bowel Disease PatientsFernando Magro, Samuel Fernandes, Marta Patita, et al.
Journal of Crohn'S & Colitis|August 12, 2025
Longitudinal Profiles of Fecal Calprotectin and C-Reactive Protein in Relation to Outcomes in Crohn's Disease Patients on InfliximabFernando Magro, Beatriz Domingues, Maria Manuela Estevinho, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|February 28, 2026
EARLY INTERVENTION PREVENTS DISEASE PROGRESSION IN ULCERATIVE COLITIS - A MULTICENTER RETROSPECTIVE STUDYJoana Camões Neves, Tiago Leal, Samuel Fernandes, et al.
United European Gastroenterology Journal|June 15, 2023
How many biomarker measurements are needed to predict prognosis in Crohn's disease patients under infliximab?-A prospective studyFernando Magro, Maria Manuela Estevinho, Gaia Catalano, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|September 13, 2020
Histologic Features of Colon Biopsies (Geboes Score) Associated With Progression of Ulcerative Colitis for the First 36 Months After BiopsyFernando Magro, Catarina Alves, Joanne Lopes, et al.
Pageof 4